Top Page
Osteopore Ltd.
(Sydney:OSX)
Osteopore Ltd. (OSX) vs. iShares MSCI Australia ETF (EWA)
Osteopore Ltd. Business Overview & Revenue Model
Osteopore Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.81M | 2.22M | 1.78M | 1.40M | 2.23M |
| Gross Profit | 2.37M | 1.64M | 1.36M | 1.10M | 1.68M |
| EBITDA | -2.34M | -4.35M | -3.97M | -3.38M | -1.76M |
| Net Income | -3.35M | -4.87M | -4.22M | -3.93M | -2.69M |
Balance Sheet | |||||
| Total Assets | 3.13M | 3.34M | 3.62M | 6.01M | 10.25M |
| Cash, Cash Equivalents and Short-Term Investments | 638.50K | 1.16M | 2.16M | 5.13M | 9.03M |
| Total Debt | 1.33M | 1.09M | 74.18K | 106.71K | 453.99K |
| Total Liabilities | 2.83M | 2.91M | 1.51M | 633.40K | 1.25M |
| Stockholders Equity | 306.22K | 432.60K | 2.11M | 5.37M | 9.00M |
Cash Flow | |||||
| Free Cash Flow | -3.10M | -3.74M | -4.06M | -4.00M | -2.14M |
| Operating Cash Flow | -3.11M | -3.74M | -4.00M | -3.81M | -1.76M |
| Investing Cash Flow | -14.59K | -7.37K | -63.98K | -194.62K | -381.04K |
| Financing Cash Flow | 2.63M | 3.58M | 842.24K | -485.88K | 7.84M |
Osteopore Ltd. Technical Analysis
Osteopore Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.36B | 0.28 | -61.07% | 2.37% | 17.46% | 1.71% | |
41 Neutral | AU$2.20M | ― | -907.51% | ― | 24.60% | 65.60% | |
| $13.79M | ― | -467.81% | ― | ― | ― | ||
| $39.67M | ― | -51.08% | ― | ― | ― | ||
| $807.54M | 65.28 | 9.23% | ― | ― | ― | ||
55 Neutral | AU$62.63M | ― | -457.46% | ― | 21.93% | 10.34% |
Osteopore Ltd. Corporate Events
Osteopore Ltd. has announced a change in the interests of a substantial holder, Advance Opportunities Fund I, which has reduced its voting power from 8.25% to 7.15% by selling 2,000,000 shares. This adjustment in shareholding could impact the company’s market dynamics and stakeholder interests, reflecting a shift in investment strategy by a significant shareholder.
Osteopore Ltd. has announced that Advance Opportunities Fund I has become a substantial holder in the company, acquiring a significant voting power with fully paid ordinary shares. This development indicates a strategic investment move, potentially impacting the company’s market positioning and shareholder dynamics.
Osteopore Ltd. has announced the issuance of 9,615,384 fully paid ordinary securities to be quoted on the ASX, effective June 19, 2025. This move is part of the company’s strategy to enhance its capital structure and support its growth initiatives, potentially strengthening its market position and providing value to its stakeholders.
Osteopore Ltd. has announced that Advance Opportunities Fund I has ceased to be a substantial holder in the company. This change in substantial holding reflects a shift in the voting securities, with the fund selling a significant number of shares, potentially impacting the company’s market dynamics and stakeholder interests.
Osteopore Ltd. has announced a change in the interests of a substantial holder, Advance Opportunities Fund I, in its voting securities. The fund has reduced its stake in Osteopore Ltd. from 6.74% to 5.52% by selling shares in the market, which may impact the company’s shareholder structure and influence in decision-making processes.
Osteopore Ltd. has reported a change in the substantial holding of its shares by Advance Opportunities Fund I. The fund’s voting power has decreased from 7.89% to 6.74%, indicating a reduction in its stake in the company. This change could impact the company’s shareholder dynamics and influence in decision-making processes.
Osteopore Limited has announced a new clinical trial in collaboration with Princess Alexandra Hospital to explore maxillomandibular reconstruction using their polycaprolactone-tricalcium phosphate scaffolds. This trial aims to assess the safety and tolerability of the technique, which could potentially offer a more adaptable and less invasive alternative to current treatments. The trial’s success could enhance Osteopore’s industry positioning and lead to further market approvals, benefiting stakeholders by potentially improving patient outcomes and expanding the company’s clinical applications.
Osteopore Ltd. announced the cessation of Daniel Ow as a director effective May 29, 2025. The notice details his relevant interests in securities, including multiple tranches of performance rights expiring in 2030. This change in directorship could impact the company’s strategic direction and stakeholder confidence, given the significant role directors play in guiding company operations.
Osteopore Limited, a company listed on the Australian Securities Exchange, held its Annual General Meeting on May 30, 2025. During the meeting, all proposed resolutions were passed, including a special resolution for a 10% placement facility, indicating strong shareholder support and potentially enhancing the company’s financial flexibility.
Osteopore Ltd. has announced the issuance of convertible notes, marking a strategic financial move to potentially enhance its capital structure. This issuance may impact the company’s operational capabilities and market positioning by providing additional resources for growth and development, potentially benefiting stakeholders through increased innovation and market reach.
Osteopore Ltd. has issued a Cleansing Notice related to its agreement with Advance Opportunities Fund for the issuance of convertible notes. This notice allows the company to issue shares upon conversion of these notes without further disclosure, facilitating retail investment. The agreement involves a subscription amount of up to $20 million, with the latest tranche amounting to $500,000. This strategic financial move is expected to enhance Osteopore’s operational capabilities and market positioning by securing necessary funding for its ongoing projects.
Osteopore Limited has announced a further drawdown of Tranche 1 of their redeemable convertible notes, with subscribers investing an additional A$500,000 in two equal sub-tranches. The funds raised will be used for the company’s ordinary business activities and potential future developments, projects, and investments. This strategic financial move supports Osteopore’s ongoing operations and growth in the regenerative medicine industry, potentially enhancing its market position and offering opportunities for stakeholders.
Osteopore Limited, in collaboration with Queensland Children’s Hospital, has initiated a clinical trial to treat temporal hollowing in children post-cranial vault remodelling surgery for craniosynostosis. This trial, which employs a 3D-printed, patient-specific polycaprolactone-tricalcium phosphate onlay scaffold, aims to assess its feasibility in restoring frontotemporal contour, potentially offering a less invasive alternative to current methods. The study has received ethical clearance and is supported by Maddox’s Helping Hand Foundation, highlighting its potential impact on improving surgical outcomes for young patients.
Osteopore Ltd. has issued a Cleansing Notice regarding the issuance of Third Convertible Notes, part of a subscription agreement with Advance Opportunities Fund. This agreement involves a subsequent investment of $500,000, allowing the company to issue shares without further disclosure to retail investors. The issuance of these convertible notes is expected to impact the company’s financial position and market operations, enhancing its ability to raise capital and expand its market presence.
Osteopore Limited has announced a further drawdown of Tranche 1 of its redeemable convertible notes, with subscribers committing to an additional A$500,000, bringing the total to A$3,500,000 out of a possible A$5,000,000 for this tranche. The funds raised will be used for the company’s ordinary business operations and future development projects, potentially enhancing Osteopore’s market positioning in the regenerative medicine industry.
Osteopore Ltd. has announced a change in the director’s interest, specifically involving Mark Leong. The notice details the various classes of securities and options held by the director, both directly and indirectly, as of May 7, 2025. This change in director’s interest is a routine disclosure that may impact the company’s governance and transparency, providing stakeholders with updated information on the director’s financial interests in the company.
Osteopore Limited has announced a change in the interests of a substantial holder, Advance Opportunities Fund I, in its voting securities. The fund’s voting power has increased from 5.62% to 7.89%, reflecting a significant shift in shareholder dynamics, which could impact the company’s strategic decisions and influence within the industry.
Osteopore Ltd. has announced the quotation of 7,812,500 new ordinary fully paid securities on the Australian Securities Exchange (ASX), effective from May 8, 2025. This move is expected to enhance the company’s capital base, potentially strengthening its market position and providing additional resources to support its operations and growth initiatives.
Osteopore Ltd. announced the issuance of 2,000,000 fully paid ordinary shares under an employee incentive scheme, which will be quoted on the Australian Securities Exchange (ASX). This move is part of the company’s ongoing efforts to incentivize and retain talent, potentially strengthening its operational capabilities and market position in the medical technology sector.
Osteopore Limited has announced that Non-Executive Director Daniel Ow will step down from the Board, effective 29 May 2025, citing personal reasons. Despite his departure, the company plans to retain Mr. Ow’s expertise by appointing him as a financial consultant, allowing Osteopore to continue benefiting from his valuable financial insights. This move is expected to maintain stability and continuity in the company’s operations and strategic direction.
Osteopore Ltd. has announced the issuance of 11,625,000 performance rights under an employee incentive scheme. These securities are unquoted and subject to transfer restrictions until the end of the restriction period. This move is likely aimed at aligning employee interests with company performance, potentially enhancing motivation and retention within the workforce.
Osteopore Ltd. has announced the application for quotation of 526,754 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of an employee incentive scheme, which may enhance employee engagement and align their interests with company growth, potentially impacting the company’s market positioning positively.
Osteopore Ltd. has announced that the Advance Opportunities Fund has become a substantial holder of its fully paid ordinary shares. The fund acquired a significant number of shares, which amounts to a 9.96% voting power in the company. This development indicates a strong vote of confidence in Osteopore’s operations and could potentially enhance its market position by attracting more investor interest.
Osteopore Ltd. has experienced a change in the substantial holding of its shares, with Advance Opportunities Fund I reducing its stake from 8.24% to 5.62%. This transaction involved the sale of 4,000,000 shares for A$66,000. The reduction in voting power could impact the company’s shareholder dynamics and influence, potentially affecting decision-making processes and strategic directions.
Osteopore Ltd. has announced the quotation of 10,869,565 fully paid ordinary shares on the Australian Securities Exchange (ASX) as of May 6, 2025. This move is expected to enhance the company’s financial flexibility and market presence, potentially impacting its operations and stakeholder interests positively by increasing its capital base.
Osteopore Limited has announced the implementation of an Employee Securities Incentive Plan. This plan aims to offer securities to eligible employees, enhancing their engagement and aligning their interests with the company’s growth objectives. The initiative is expected to strengthen employee commitment and potentially improve the company’s operational performance.
Osteopore Limited has entered into an exclusive two-year distribution agreement with Peakmed Co., Ltd, a Thailand-based medical device company, to distribute its craniofacial implants across 70 hospitals in Thailand. This strategic partnership aims to strengthen Osteopore’s market presence in Thailand, a key market due to the high volume of neurosurgical procedures, and aligns with the company’s strategy to expand its distribution channels in the growing Southeast Asian healthcare market.
Osteopore Ltd. has experienced a change in the interests of a substantial holder, Advance Opportunities Fund I, which has adjusted its voting power from 9.75% to 8.24% through a series of transactions involving fully paid ordinary shares. This shift in shareholding could impact the company’s market dynamics and influence its strategic decisions, reflecting a potential change in investor confidence or strategy.
Osteopore Ltd. has announced a change in the substantial holding of its shares by Advance Opportunities Fund I. The fund has reduced its voting power from 11.23% to 9.75% by selling 2,250,000 shares in the market. This change in shareholding could impact the company’s stock market dynamics and influence its strategic decisions, as a significant stakeholder has altered its investment position.
Osteopore Ltd. has announced the scheduling of its Annual General Meeting (AGM) for shareholders on May 30, 2025, in Perth, Australia. The company encourages shareholders to participate either in person or by proxy, emphasizing the importance of reviewing the Notice of Meeting for detailed information. This meeting is a significant event for stakeholders as it provides an opportunity to discuss the company’s strategic direction and operational updates.
Osteopore Limited has achieved a significant milestone by having its craniomaxillofacial and oculoplastic implants listed on Singapore’s Ministry of Health Implant Subsidy List, which will enhance accessibility for patients and potentially increase market penetration. Additionally, the company has initiated financial strategies by drawing down Tranche 1 of its Redeemable Convertible Note with the Advance Opportunities Fund, securing A$2 million, which may bolster its financial position and operational capabilities.
Osteopore Ltd. has announced the issuance of 6,493,506 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX). This move is expected to enhance the company’s capital structure and potentially improve its market positioning by increasing liquidity and investor interest.
Osteopore Ltd. has announced a change in the substantial holding of its shares by Advance Opportunities Fund I. The fund’s voting power in Osteopore has decreased from 11.26% to 10.21%, reflecting a reduction in their holding of fully paid ordinary shares. This adjustment in shareholding may influence the company’s market dynamics and stakeholder relations, as changes in substantial holdings can impact investor confidence and company governance.
Osteopore Ltd. announced the quotation of 5,376,344 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of April 23, 2025. This move is a significant step for the company, potentially enhancing its market presence and providing additional capital for growth and development, which could positively impact stakeholders and strengthen its position in the medical technology industry.
Osteopore Ltd. has announced a change in the interests of a substantial holder, Advance Opportunities Fund I, in its voting securities. The fund’s voting power decreased from 12.72% to 11.26% following a transaction involving fully paid ordinary shares. This change reflects a shift in the fund’s investment position within the company, potentially impacting its influence on corporate decisions.
Osteopore Ltd. has announced a change in the interests of a substantial holder, Advance Opportunities Fund I, which has decreased its voting power from 13.88% to 12.72%. This adjustment reflects a shift in the fund’s holdings, potentially impacting the company’s shareholder structure and market perception.
Osteopore Ltd. has announced a change in the interests of a substantial holder, Advance Opportunities Fund I, in its voting securities. The fund’s voting power has decreased slightly from 14.2% to 13.88% due to a reduction of 500,000 shares. This change may impact the company’s shareholder dynamics and influence its strategic decisions moving forward.
Osteopore Ltd. has experienced a change in the interests of a substantial holder, Advance Opportunities Fund I, which now holds 19,980,519 fully paid ordinary shares, representing a 14.2% voting power in the company. This change in shareholding could impact Osteopore’s strategic decisions and influence its market positioning, as substantial holders often play a significant role in corporate governance and decision-making.
Osteopore Ltd. has announced that Advance Opportunities Fund I has become a substantial holder in the company. The fund has acquired 19,480,519 fully paid ordinary shares, representing a 13.88% voting power in Osteopore Ltd., with a consideration of A$300,000. This acquisition could potentially influence the company’s strategic decisions and impact its market positioning.
Osteopore Ltd. announced the quotation of 19,480,519 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategic efforts to enhance its market presence and provide additional liquidity for its stakeholders, potentially strengthening its position in the regenerative medicine industry.
Osteopore Limited has secured European Union Medical Device Regulation approval for its custom orthopaedic and cranial implants, allowing it to expand its market presence in Europe. This regulatory clearance, combined with an exclusive distribution agreement with Zimmer Biomet, positions Osteopore to tap into the growing European markets for orthopaedic and cranial implants, potentially unlocking new revenue streams and strengthening its industry position.
Osteopore Ltd. has announced a correction to a previous update regarding the proposed issue of securities, specifically addressing an approval at a shareholder meeting. This update is part of their ongoing efforts to ensure compliance with ASX Listing Rules and maintain transparency with stakeholders, potentially impacting the company’s financial strategies and market positioning.
Osteopore Limited has announced the date for its Annual General Meeting, set for May 30, 2025. The meeting will include the re-election and appointment of directors, with nominations closing on April 18, 2025. This announcement is part of Osteopore’s ongoing efforts to strengthen its leadership and maintain its position as a leader in the regenerative medicine industry, potentially impacting its strategic direction and stakeholder relations.
Osteopore Limited, a company listed on the Australian Securities Exchange, has announced the lifting of the suspension of its securities trading. This reinstatement follows the submission of its Annual Financial Report for the year ending December 31, 2024, indicating a return to regular market activity.
Osteopore Ltd. has released its corporate governance statement for the financial year ending December 31, 2024, in compliance with ASX Listing Rules. The statement, available on the company’s website, outlines the extent to which Osteopore has adhered to the ASX Corporate Governance Council’s recommendations. This disclosure is significant as it provides transparency and assurance to stakeholders regarding the company’s governance practices, potentially impacting investor confidence and market positioning.
Osteopore Limited has released its consolidated annual report for the year ending December 31, 2024. The report includes updates on the company’s corporate structure, including the appointment of Lim Yujing as a director and Jack Rosagro as the company secretary. These changes in leadership could impact the company’s strategic direction and operational efficiency.
Osteopore Limited has announced the further drawdown of Tranche 1 of their redeemable convertible notes, raising an additional A$1,000,000. This funding will support the company’s ongoing business operations and potential future projects, enhancing their financial flexibility and capacity for growth in the regenerative medicine sector.
Osteopore Ltd. has announced a delay in the submission of its Annual Report for the financial year ended 31 December 2024, due to unforeseen staffing resource challenges affecting the compilation of necessary information for auditors. The company emphasizes its commitment to meeting reporting obligations and plans to submit the report as soon as possible, highlighting the importance of transparency and compliance for its stakeholders.
Osteopore Ltd. has announced a proposed issue of convertible notes, with a maximum of 20 securities to be issued. This move is part of a strategic effort to enhance its financial position, potentially impacting its operations and market standing by providing additional capital for growth and development.
Osteopore Ltd. has issued a prospectus for an offer of 20 convertible notes, each valued at $50,000. The prospectus is a transaction-specific document prepared in accordance with the Corporations Act, focusing on the effect of the securities issue and the rights attached to them. The offer is considered highly speculative, and investors are advised to read the document thoroughly and seek professional advice. The company is a disclosing entity, subject to continuous disclosure obligations, and the securities are not offered in certain jurisdictions, including the United States and the Cayman Islands.
Osteopore Limited has announced the opening of a Clinical Centre of Excellence (CCoE) for medial wedge opening high tibial osteotomy (MOWHTO) in collaboration with Total Orthopaedic Care & Surgery. This initiative, led by renowned orthopaedic surgeon Dr. Hamid Razak, aims to enhance the understanding and adoption of MOWHTO techniques among clinicians, providing training and educational sessions to improve patient outcomes. The centre’s establishment follows recent approvals and strategic partnerships, reinforcing Osteopore’s commitment to innovative knee preservation techniques that delay the need for total knee arthroplasty.